Skip to main content

REVIEW article

Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1443784

PIM1 signalling in immunoinflammatory diseases: an emerging therapeutic target

Provisionally accepted
Xue Yang Xue Yang 1,2Chunming Liu Chunming Liu 2Xue Liu Xue Liu 1Bin Zhu Bin Zhu 1*Dongchi Zhao Dongchi Zhao 2*
  • 1 Department of Pediatrics, Xiangyang Central Hospital, Xiangyang, China
  • 2 Zhongnan Hospital, Wuhan University, Wuhan, Hubei Province, China

The final, formatted version of the article will be published soon.

    PIM1, the proviral integration site for Moloney murine leukaemia virus, is a member of the serine/threonine protein kinase family. It is involved in many biological events, such as cell survival, cell cycle progression, cell proliferation, and cell migration, and has been widely studied in malignant diseases.However, recent studies have shown that PIM1 plays a prominent role in immunoinflammatory diseases, including autoimmune uveitis, inflammatory bowel disease, asthma, and rheumatoid arthritis. PIM1 can function in inflammatory signal transduction by phosphorylating multiple inflammatory protein substrates and mediating macrophage activation and T lymphocyte cell specification, thus participating in the development of multiple immunoinflammatory diseases. Moreover, the inhibition of PIM1 has been demonstrated to ameliorate certain immunoinflammatory disorders. Based on these studies, we suggest PIM1 as a potential therapeutic target for immunoinflammatory diseases and a valid candidate for future research.Herein, for the first time, we provide a detailed review that focuses on the roles of PIM1 in the pathogenesis of immunoinflammatory diseases.

    Keywords: PIM1, Serine/threonine protein kinase, Immunoinflammatory disease, inflammatory bowel disease, Rheumatoid arthritis

    Received: 04 Jun 2024; Accepted: 02 Sep 2024.

    Copyright: © 2024 Yang, Liu, Liu, Zhu and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Bin Zhu, Department of Pediatrics, Xiangyang Central Hospital, Xiangyang, China
    Dongchi Zhao, Zhongnan Hospital, Wuhan University, Wuhan, 430071, Hubei Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.